Liquid biopsy of extracellular vesicle biomarkers for prostate cancer personalized treatment decision

Extracellular vesicles and circulating nucleic acids Pub Date : 2022-01-01 DOI:10.20517/evcna.2021.20

Meng Han, Bairen Pang, Cheng Zhou, Xin Li, Qi Wang, Junhui Jiang, Yong Li

{"title":"Liquid biopsy of extracellular vesicle biomarkers for prostate cancer personalized treatment decision","authors":"Meng Han, Bairen Pang, Cheng Zhou, Xin Li, Qi Wang, Junhui Jiang, Yong Li","doi":"10.20517/evcna.2021.20","DOIUrl":null,"url":null,"abstract":"Liquid biopsy of tumor-derived extracellular vesicles (EVs) has great potential as a biomarker source for prostate cancer (CaP) early diagnosis and predicting the stages of cancer. The contents of EVs play an important role in intercellular communication and have specific expression in blood and urine samples from CaP patients. Powered by high-throughput, next-generation sequencing and proteomic technologies, novel EV biomarkers are easily detected in a non-invasive manner in different stages of CaP patients. These identified potential biomarkers can be further validated with a large sample size, machine learning model, and other different methods to improve the sensitivity and specificity of CaP diagnosis. The EV-based liquid biopsy is a novel and less-invasive alternative to surgical biopsies which would enable clinicians to potentially discover a whole picture of tumor through a simple blood or urine sample. In summary, this approach holds promise for developing personalized medicine to guide treatment decisions precisely for CaP patients.","PeriodicalId":73008,"journal":{"name":"Extracellular vesicles and circulating nucleic acids","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Extracellular vesicles and circulating nucleic acids","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20517/evcna.2021.20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 5

Abstract

Liquid biopsy of tumor-derived extracellular vesicles (EVs) has great potential as a biomarker source for prostate cancer (CaP) early diagnosis and predicting the stages of cancer. The contents of EVs play an important role in intercellular communication and have specific expression in blood and urine samples from CaP patients. Powered by high-throughput, next-generation sequencing and proteomic technologies, novel EV biomarkers are easily detected in a non-invasive manner in different stages of CaP patients. These identified potential biomarkers can be further validated with a large sample size, machine learning model, and other different methods to improve the sensitivity and specificity of CaP diagnosis. The EV-based liquid biopsy is a novel and less-invasive alternative to surgical biopsies which would enable clinicians to potentially discover a whole picture of tumor through a simple blood or urine sample. In summary, this approach holds promise for developing personalized medicine to guide treatment decisions precisely for CaP patients.

查看原文本刊更多论文

细胞外囊泡液体活检生物标志物对前列腺癌个性化治疗决策的影响

肿瘤来源的细胞外囊泡(EVs)液体活检作为前列腺癌(CaP)早期诊断和预测癌症分期的生物标志物来源具有很大的潜力。EVs的含量在细胞间通讯中起重要作用，在CaP患者的血液和尿液样本中有特异性表达。在高通量、新一代测序和蛋白质组学技术的支持下，新的EV生物标志物可以在不同阶段的CaP患者中以无创方式轻松检测到。这些确定的潜在生物标志物可以通过大样本量、机器学习模型和其他不同的方法进一步验证，以提高CaP诊断的敏感性和特异性。基于ev的液体活检是外科活检的一种新颖且侵入性较小的替代方法，它将使临床医生能够通过简单的血液或尿液样本发现肿瘤的全貌。总之，这种方法有望为CaP患者开发个性化的药物，以精确地指导治疗决策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Extracellular vesicles and circulating nucleic acids

CiteScore

4.10

自引率

0.00%

发文量